These studies from the ASCO Annual Meeting show some of the newest thoughts and latest advances in using immunotherapy and targeted therapy to treat bladder, stomach, and lung cancers.

From June 3 to June 7, oncology professionals from around the world will meet to discuss the latest in cancer research. If you can’t wait to learn about the latest research, check here for early highlights released in advance of the 2016 ASCO Annual Meeting.

Immunotherapy made exciting strides in 2015. Because of its potential, ASCO named it the 2016 Clinical Cancer Advance of the Year.

Immunotherapy is one of the hottest topics in cancer research. This year, focus at the ASCO Annual Meeting has been on a type of immunotherapy called PD-1 inhibitors. Learn how these drugs may help improve the treatment of head and neck, liver, and lung cancers.